18:17 , Jan 11, 2019 |  BC Week In Review  |  Company News

Regeneron, Sanofi narrow focus of immuno-oncology deal

By narrowing the focus of a 2015 immuno-oncology deal, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) gains more freedom to play in its combinations sandbox as partner Sanofi (Euronext:SAN; NASDAQ:SNY) turns to other immuno-oncology agents in its pipeline....
21:05 , Jan 10, 2019 |  BC Innovations  |  Emerging Company Profile

Kleo: small molecule immuno-oncology

Kleo Pharmaceuticals Inc. is tapping small molecules' advantages over biologics by synthesizing compounds that mimic or modify the functions of antibodies as cancer immunotherapies. The company spun out of Yale University in 2015 with IP...
00:11 , Jan 8, 2019 |  BC Extra  |  Company News

Regeneron, Sanofi narrow focus of immuno-oncology deal

By narrowing the focus of a 2015 immuno-oncology deal, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) gains more freedom to play in its combinations sandbox as partner Sanofi (Euronext:SAN; NASDAQ:SNY) turns to other immuno-oncology agents in its pipeline....
02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
22:03 , Jan 4, 2019 |  BC Week In Review  |  Financial News

On heels of series C, Harpoon files for IPO

Less than two months after raising a $70 million series C round, Harpoon Therapeutics Inc. (South San Francisco, Calif.) filed on Dec. 27 to raise $86.3 million in an IPO on NASDAQ. Harpoon is developing...
23:06 , Dec 27, 2018 |  BC Extra  |  Financial News

On heels of series C, Harpoon files for IPO

Less than two months after raising a $70 million series C round, Harpoon Therapeutics Inc. (South San Francisco, Calif.) filed Thursday to raise $86.3 million in an IPO on NASDAQ. Harpoon is developing tri-specific T...
21:07 , Dec 14, 2018 |  BC Week In Review  |  Clinical News

FDA places hold on Phase I trials of MacroGenics' bispecific molecule due to hepatic events

MacroGenics Inc. (NASDAQ: MGNX) said FDA placed a partial clinical hold on two Phase I trials of MGD009 to treat cancer after the company reported hepatic adverse events in one of the trials that is...
02:33 , Dec 8, 2018 |  BioCentury  |  Product Development

Intermittent move beyond Blincyto

A swath of data at ASH shows that companies have been able to move beyond the 28-day continuous dosing of Amgen Inc.’s first-generation BiTE, Blincyto, to build next-generation antibodies with more convenient, intermittent dosing and...
18:31 , Dec 7, 2018 |  BC Week In Review  |  Clinical News

Regeneron planning Phase II for REGN1979 in lymphoma following ASH readout

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) plans to start next year a "potentially registrational" Phase II trial of REGN1979 to treat relapsed or refractory follicular lymphoma after reporting an overall response rate (ORR) of 100% in a...
17:51 , Dec 7, 2018 |  BC Week In Review  |  Clinical News

New BCMA-targeted therapies could help sicker patients

Oral abstracts at this year’s American Society of Hematology meeting describing next generation anti-BCMA CARs from Poseida Therapeutics Inc. and Fred Hutchinson Cancer Research Center and a bispecific antibody from Amgen Inc. (NASDAQ:AMGN) hint that...